Delving into the Latest Updates on Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Respiratory Diseases

Immune System Diseases

Small molecule drug

Biological products

Herbal medicine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	2
Endocrinology and Metabolic Disease	2
Hemic and Lymphatic Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	3
Unknown	2
Biological products	1
Herbal medicine	1

Top 5 Target	Count

AR(Androgen Receptor)	1
HIF-PHs(Hypoxia-inducible factor prolyl hydroxylase)	1
ABCC9 x Kir6.2	1

This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of 1% Clascoterone Cream in the treatment of acne vulgaris.
Target population: Participants aged ≥12 years with moderate to severe acne vulgaris who meet the inclusion criteria and none of the exclusion criteria.
Treatment: The investigational group will receive 1% Clascoterone Cream, and the control group will receive placebo. Approximately 1 g of the cream will be applied evenly to the entire face twice daily (morning and evening) for 12 weeks.

Start Date04 May 2026

Sponsor / Collaborator

Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

NCT07080931

/ RecruitingPhase 3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study on the Efficacy and Safety of 5% Minoxidil Foam in the Treatment of Female Androgenetic Alopecia

The primary objective of this study is to evaluate the efficacy of once-daily 5% minoxidil foam versus placebo in female androgenetic alopecia, using the Target Area Terminal Hair Count (TAHC) as the primary endpoint.

Start Date24 Feb 2025

Sponsor / Collaborator

Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

CTR20242817

/ CompletedNot Applicable

盐酸二甲双胍缓释片人体生物等效性试验

[Translation] Bioequivalence study of metformin hydrochloride sustained-release tablets in humans

主要目的：比较空腹及餐后给药条件下，浙江三生蔓迪药业有限公司提供的盐酸二甲双胍缓释片（规格：0.5 g）与Merck Serono Limited持证的盐酸二甲双胍缓释片（商品名：Glucophage XR®/格华止®；规格：0.5 g）在健康人群中吸收程度和速度的差异。次要目的：评价空腹及餐后给药条件下，浙江三生蔓迪药业有限公司提供的盐酸二甲双胍缓释片（规格：0.5 g）与Merck Serono Limited持证的盐酸二甲双胍缓释片（商品名：Glucophage XR®/格华止®；规格：0.5 g）的安全性。

[Translation]

Primary objective: To compare the differences in absorption degree and speed of metformin hydrochloride sustained-release tablets (specification: 0.5 g) provided by Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd. and metformin hydrochloride sustained-release tablets (trade name: Glucophage XR®/Glucophage®; specification: 0.5 g) certified by Merck Serono Limited in healthy people under fasting and postprandial administration conditions. Secondary objective: To evaluate the safety of metformin hydrochloride sustained-release tablets (specification: 0.5 g) provided by Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd. and metformin hydrochloride sustained-release tablets (trade name: Glucophage XR®/Glucophage®; specification: 0.5 g) certified by Merck Serono Limited under fasting and postprandial administration conditions.

Start Date19 Sep 2024

Sponsor / Collaborator

Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

100 Clinical Results associated with Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

Login to view more data

0 Patents (Medical) associated with Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

Login to view more data

100 Deals associated with Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

Login to view more data

100 Translational Medicine associated with Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Jun 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

1

Phase 2

Phase 3

1

3

Approved

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Minoxidil ( ABCC9 x Kir6.2 )	Alopecia Areata More	Approved
BCG polysaccharide and nucleic acid(Zhejiang Wansheng Pharmaceutical Co., Ltd.)	Asthma More	Approved
Qi ming granula	Diabetic Retinopathy More	Approved
Clascoterone ( AR )	Acne Vulgaris More	Phase 3
SSS-17 ( HIF-PHs )	Anemia of renal disease More	Phase 2